Sequence Referral Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 0.80 M
as on 09-12-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 224.12%
(FY 2022)
- Profit 1509.25%
(FY 2022)
- Ebitda 1294.23%
(FY 2022)
- Net Worth 2264.38%
(FY 2022)
- Total Assets 98.96%
(FY 2022)
About Sequence Referral Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Aakanksha Singhal and Anita Singhal serve as directors at the Company.
- CIN/LLPIN
U85100DL2010PTC206290
- Company No.
206290
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jul 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sequence Referral Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aakanksha Singhal  | Director | 15-May-2014 | Current |
| Anita Singhal | Director | 12-May-2018 | Current |
Financial Performance of Sequence Referral Laboratories.
Sequence Referral Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 224.12% increase. The company also saw a substantial improvement in profitability, with a 1509.25% increase in profit. The company's net worth Soared by an impressive increase of 2264.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sequence Referral Laboratories?
In 2021, Sequence Referral Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Genome Diagnostics Private LimitedActive 21 years 1 monthAakanksha Singhal and Anita Singhal are mutual person
Real Time Instrumentation Private LimitedActive 21 years 3 monthsAakanksha Singhal and Anita Singhal are mutual person
Professional Biotech Private LimitedActive 28 years 7 monthsAakanksha Singhal and Anita Singhal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sequence Referral Laboratories?
Unlock and access historical data on people associated with Sequence Referral Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sequence Referral Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sequence Referral Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
